Compare Adaptive Biotechnologies Corp (ADPT) vs Verisign, Inc. (VRSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Verisign, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Verisign, Inc. trades at $269.67 (market cap $24.28B). The key difference: Verisign, Inc. is far larger — about 7.3× Adaptive Biotechnologies Corp's market cap, and Verisign, Inc. pays a 1.21% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | VRSN | |
|---|---|---|
Market Cap | $3.33B | $24.28B |
Sector | Health | Technology |
52-Week High | $22.37 | $310.00 |
52-Week Low | $10.24 | $211.49 |
Enterprise Value | $3.19B | $25.52B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VeriSign (VRSN) trades at $266.78, up 4.04% on the day, with a bearish technical signal and mixed earnings history including a Q1 2026 beat. The stock shows strong fundamentals with 49.96% net income margin and $825.7M net income for 2025, though negative shareholder equity remains a concern. Recent news highlights AI-driven domain growth and upcoming Q2 2026 earnings.
Outlook is cautiously optimistic with 57% analyst buy ratings and a $327.67 consensus target offering 23% upside. Key risks include contract renewals, AI disruption potential, and high debt levels. Revenue growth stability and margin strength support investment case, but technical resistance near $266 requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
